Recent

% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

ckfun1 82 posts  |  Last Activity: 1 minute 16 seconds ago Member since: Apr 23, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Okay who was it?

    by stock_lurker Jul 28, 2015 9:56 AM
    ckfun1 ckfun1 1 minute 16 seconds ago Flag

    No one was worrying...just stating the price when someone didn't think TTPH would be in the $46s again.
    No need for CAPS either.
    ~ck (long)

  • Reply to

    Okay who was it?

    by stock_lurker Jul 28, 2015 9:56 AM
    ckfun1 ckfun1 2 hours 15 minutes ago Flag

    Be careful what you wish for...trading at $46.50...not a good day for TTPH.
    ~ck (long)

  • Reply to

    So let us reexamine blue's post froma month ago

    by dkoeper Jul 27, 2015 3:18 PM
    ckfun1 ckfun1 Jul 27, 2015 4:57 PM Flag

    Blue,
    Totally agree with your analysis of the situation.
    The scripts are the only thing that matters and they do not show growth.
    The cheerleaders can paint this anyway they want, but the only thing that counts is numbers.
    ~ck (long and watching profit evaporate)

  • ckfun1 ckfun1 Jul 27, 2015 4:48 PM Flag

    I am considering buying some shares.
    I am familiar with high optic pressure. I had PDS after cataract surgery and it caused a drainage blockage therefore raising my OP to dangerous levels. The second tim eit was worse.
    How does this compare to combigan, alphagan or others?
    Thank you in advance.
    ~ck

  • Reply to

    New CFO

    by comeonmonday Jul 27, 2015 8:06 AM
    ckfun1 ckfun1 Jul 27, 2015 8:08 AM Flag

    At least Holmes comes from AMAG.. that stock went from 17 to 77 and AMAG is actually profitable.
    Perhaps he will bring some savvy to this lackluster management team.
    He was controller of KERX back in the day.
    ~ck

  • ckfun1 ckfun1 Jul 23, 2015 11:09 AM Flag

    I have been a shareholder for a long time and this is one of my biggest losers. My original cost is too high to even talk about.
    I have not followed the science for awhile (I own too many biotechs) and would appreciate any updates about the status of their research.
    I am hoping there is some light at the end of the tunnel. The stock price is in the tank...
    Thank you.
    ~ck

  • Reply to

    May 7 post

    by imdogginit Jul 11, 2015 1:32 AM
    ckfun1 ckfun1 Jul 15, 2015 11:48 AM Flag

    Something good this way comes.
    I think given the price action and the new hire announcement of Dumas, we have solid Ph III data coming sooner rather than later.
    ~ck (wish I had more shares)

    Sentiment: Strong Buy

  • Just announed this morning there will be an earnings conference on July 31 at 8AM to discuss June results.
    They will also be giving drug/FDA updates...could be interesting and a big day.
    ~ck (very long)

    Sentiment: Strong Buy

  • ckfun1 ckfun1 Jul 14, 2015 7:54 AM Flag

    They are a partner with CYTK on Omecamtiv:
    Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.

    ~ck (long)

    Sentiment: Strong Buy

  • ckfun1 ckfun1 Jul 13, 2015 2:00 PM Flag

    Life is full of disappointments: HZNP response to poison pill:
    We are very disappointed that instead of listening to its shareholders and immediately entering into negotiations with Horizon, the Depomed Board has instead taken actions to limit its shareholders' opportunity to maximize the value of their investment by implementing a poison pill and adopting changes to their bylaws that would, among other things, enable their Board of Directors to delay and make more difficult the calling of a special meeting of its shareholders. Horizon's proposal represents a premium of 42 percent to the closing price of Depomed's stock on July 6, 2015 and will yield significant strategic and financial benefits to shareholders of both companies. We urge the Depomed Board to stop taking actions to frustrate the will of their shareholders and engage with us to negotiate a mutually acceptable transaction."

    ~ck (long)

  • Reply to

    HZNP will make an offer for $35/Share ?

    by infovijay2k Jul 10, 2015 12:00 PM
    ckfun1 ckfun1 Jul 13, 2015 7:09 AM Flag

    There has been a poison pill put into place by DEPO:
    Depomed Inc. ( DEPO

    Loading...
    ) disclosed Monday that it has taken steps to shield itself from a hostile takeover, about a week after Horizon Pharma PLC ( HZNP

    Loading...
    ) took its proposal to buy the company for $1.75 billion public.
    In a securities filing, Depomed ( DEPO

    Loading...
    ) said it has adopted a poison-pill plan that would be triggered by a person or group acquiring a more than 10% stake in the company. A poison pill, or shareholder rights plan, is designed to dilute the value of stock by flooding the market with additional shares, making it more difficult for an investor to acquire a controlling stake.
    Horizon said last week that it made the offer to buy Depomed ( DEPO

    Loading...
    ) in a letter sent May 27, but that Depomed ( DEPO

    Loading...
    ) had rejected the proposal. Horizon said it went public with its offer because Depomed ( DEPO

    Loading...
    ) executives have refused to engage in talks with Horizon.
    In response, Depomed's ( DEPO

    Loading...
    ) board stated that the proposal was "not in the best interest" of the company, given that it is in a period of "significant growth" and is expected to benefit from its recent acquisition of the painkiller Nucynta from Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson.

  • ckfun1 ckfun1 Jul 10, 2015 8:35 AM Flag

    Planned sale:

    The sale was effected pursuant to a Rule 10b5-1 trading plan.
    ~ck (new shareholder)

  • Reply to

    NCE

    by rayonman11 Jul 7, 2015 9:25 PM
    ckfun1 ckfun1 Jul 8, 2015 1:13 PM Flag

    Zing,
    I don't believe it is just the shorts creating the downturn in KERX. My thoughts have not been well received on this MB either.
    I have been long for a long time and am starting to wonder if it is just time to cash out. Sooner would have been better, obviously
    What are your thoughts?
    ~ck

  • Reply to

    More Than $29.25

    by schieboutz Jul 7, 2015 12:20 PM
    ckfun1 ckfun1 Jul 7, 2015 1:33 PM Flag

    There is an article at Zack's that states the price is too low.
    I'm holding all my shares for a better price which I believe will happen.
    ~ck (long)

  • Reply to

    AF hit piece today

    by pentech50 Jul 7, 2015 7:59 AM
    ckfun1 ckfun1 Jul 7, 2015 8:15 AM Flag

    At some point, management has to take some of the blame.
    AF has never been a KERX fan, but I wish I had sold the rest of my shares at $15 instead of buying more around $10-11.
    One of my other biotech holdings, DEPO, has had a hostile takeover bid this morning.
    Maybe we can interest Horizon in KERX., instead..
    ~ck (long)

  • Reply to

    DEPO Bought

    by billydbaseball Jul 7, 2015 7:09 AM
    ckfun1 ckfun1 Jul 7, 2015 7:32 AM Flag

    Yes..will have to research the Funds that own DEPO. Little guys like us don't really count.
    Does not show a time when the stock will start trading again...just a code T2
    ~ck

  • Reply to

    DEPO Bought

    by billydbaseball Jul 7, 2015 7:09 AM
    ckfun1 ckfun1 Jul 7, 2015 7:24 AM Flag

    no...just the opposite...

  • Reply to

    DEPO Bought

    by billydbaseball Jul 7, 2015 7:09 AM
    ckfun1 ckfun1 Jul 7, 2015 7:22 AM Flag

    7:15 EDT - Down 27% from April's record high, Depomed ( DEPO

    Loading...
    ) is going to surge anew today amid Horizon Pharma's ( HZNP

    Loading...
    ) $1.75B all-stock buyout offer, a deal the biopharma firm says would "immediately and substantially" boost adjusted EPS. "Given the significant revenue and operating synergies, as well as considerable tax savings, we would create substantial long-term value for Depomed's ( DEPO

    Loading...
    ) shareholders in addition to the immediate value realized through the proposed premium," says CEO Timothy Walbert. HZNP releases a bear-hug letter dated today which discloses a $29.25/share offer made in May that it says DEPO has rejected, while adding officials have refused to engage. DEPO closed yesterday at $20.64 and it was halted ahead of the disclosure; HZNP rises 5.7% premarket to what would be a new record.

  • Reply to

    DEPO Bought

    by billydbaseball Jul 7, 2015 7:09 AM
    ckfun1 ckfun1 Jul 7, 2015 7:16 AM Flag

    Yes...I was hoping for a much higher price...

  • There is a new article about short sellers and KERX etc in today's Bizjournal/Boston. It is in the news section on this KERX Yahoo page.
    Today's market could be dicey with the Greek drama and China playing out.
    ~ck (long)

    Sentiment: Strong Buy

ELN
18.120.00(0.00%)Dec 18 3:59 PMEST